CLRB
Cellectar Biosciences, Inc.Marquee-fund ownership over time
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 3× in & out | Q4 2025 | Q1 2026 | → $3.12 | +8% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | → $3.14 | +9% |
| Two Sigma Investments | Q1 2025 | Q3 2025 | — | +0% |
| Millennium Management | Q3 2024 | Q4 2024 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Cellectar Biosciences, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 11, 2026 — the most recent Form 4 on file — not from today.
- Form 40001104659-26-058854May 11, 2026
- Form 40001104659-26-058851May 11, 2026
- Form 40001104659-25-121691Dec 16, 2025
- Form 40001104659-25-065573Jul 3, 2025
- Form 40001104659-25-065572Jul 3, 2025
- Form 40001104659-25-065570Jul 3, 2025
- Form 40001104659-25-023121Mar 12, 2025
- Form 40001104659-25-014757Feb 18, 2025
- Form 40001104659-25-014753Feb 18, 2025
- Form 40001104659-25-014752Feb 18, 2025
- Form 40001104659-25-014744Feb 18, 2025
- Form 40001104659-25-014742Feb 18, 2025
- Form 40001104659-25-014740Feb 18, 2025
- Form 40001104659-25-014737Feb 18, 2025
- Form 40001104659-25-014730Feb 18, 2025
Fundamentals
XBRL · Cellectar Biosciences, Inc.Annual figures sourced directly from Cellectar Biosciences, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Cellectar Biosciences, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- S-1/AFORM S-1/AMay 29, 2026
- DEF 14AProxy statementMay 28, 2026
- S-1FORM S-1May 19, 2026
- 8-KFORM 8-KMay 18, 2026
- 8-KFORM 8-KMay 14, 2026
- 10-QQuarterly reportMay 14, 2026
- 8-KFORM 8-KMay 8, 2026
- 10-K/AAnnual report (amended)Apr 30, 2026
- 8-KFORM 8-KMar 4, 2026
- 10-KAnnual reportMar 4, 2026
- 8-KFORM 8-KNov 13, 2025
- 10-QQuarterly reportNov 13, 2025
- S-1FORM S-1Oct 20, 2025
- 8-KFORM 8-KOct 10, 2025
- 8-KFORM 8-KOct 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q4 2025 | Q1 2026 | $2.90 | $3.12 | +8% |
| Renaissance Technologies | Q4 2025 | Q1 2026 | $2.87 | $3.14 | +9% |
| Citadel Advisors | Q2 2025 | Q3 2025 | $0.00 | — | +0% |
| Two Sigma Investments | Q1 2025 | Q3 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q4 2024 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.